---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-005767"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2024-04-25T23:59:59+00:00"
generated_at: "2026-06-03T07:23:02.645702+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics Q1 total revenue $210M, net loss narrows to $91.6M; pipeline milestones on track

## Summary
- Q1 total revenue $210M (down ~5% YoY); DMD franchise $161M (Translarna $104M, Emflaza $57M).
- GAAP net loss $91.6M, improved from $139M loss in Q1 2023; cash $884.8M.
- Submitted MAA for sepiapterin (PKU) and BLA for Upstaza (AADC deficiency) in March 2024.
- Plans to resubmit Translarna NDA mid-2024; PIVOT-HD (PTC518) interim data in Q2 2024.
- Reaffirmed FY2024 total revenue guidance $600-680M; GAAP R&D/SG&A $740-835M.

## SEC filing metadata
- accession: 0001558370-24-005767
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2024-04-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000155837024005767/0001558370-24-005767-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000155837024005767/tmb-20240425x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-005767
- JSON: https://secwatch.observer/filing/0001558370-24-005767.json
- Plain text: https://secwatch.observer/filing/0001558370-24-005767.txt

## Key facts
- Earnings Releases
  PTC THERAPEUTICS, INC. reported the first quarter ending March 31, 2024 results: revenue $210.1 million, net income $91.6 million. Guidance reaffirmed.
  - Period: the first quarter ending March 31, 2024
  - Revenue: $210.1 million
  - Net income: $91.6 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: many planned 2024 clinical and regulatory milestones, including global regulatory submissions for sepiapterin." ​ Key Corporate Updates: ● First quarter 2024 total revenue of $210 million ● First quarter 2024 revenue for the DMD franchise was $161 million o TranslarnaTM (ataluren) net product revenue was $104 million, driven by new patients in existing geographies
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000155837024005767/0001558370-24-005767-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.